Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:11/30/2007

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

Abstract # 443: oral presentation

Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase

Inhibitor in Elderly and/or Treatment Refractory Patients with Acute

Myeloid Leukemia

Location and timing: Acute Myeloid Leukemias: Therapy, excluding

Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,

2007, 13:30-15:00 Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

Abstract # 1608, Poster # 762

Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of

AML by the Novel Agent CHR-2797

Location and timing: Poster Session I, Hall B4: Saturday, December 8,

2007, 17:30-19:30 Eastern Standard Time

Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)

Abstract # 2505, Poster # 695

Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in

Myeloma

Location and timing: Poster Session II, Hall B4: Sunday, December 9,

2007, 18:00-20:00, Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

The ASH posters will be available at the company's website, http://www.chromatherapeutics.com following the above presentations.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... disorder, but concern for women who become dependent on opioid painkillers has fallen short. ... female patients, compared to a 237% increase in fatal overdoses in male populations.(1) , ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Orange County ... a chronic inflammatory gum condition that occurs when the bacteria in plaque infect the ... referred to as a scaling and root planing or SRP, and can include surgical ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – ... disclosed that despite scientific studies, the Center for Disease Control ( CDC ) and ... . Kenneth B. Liegner, M.D. has compiled into a single volume a compelling ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... , Feb. 24, 2017  Today, exocad America ... labs have a new path to produce 510(K) ... Biodenta implant library integrated into exocad DentalCAD software. ... FDA compliant Good Manufacturing Processes (GMP,s) into their ... Biodenta, and complete an audit process. Then, dental labs ...
Breaking Medicine Technology: